Survival Outcome Prediction in Lung Cancer Patients with Brain Metastases: A Brief Review of Recent Studies

By
Sifat Jahan Shorna
Sreya Majumder
Diya Rahman
Fariha Jahan
Sheak Rashed Haider Noori
Liew Tze Hui
Dip Nandi
Mashiour Rahman
July 14, 2026

Frontiers In Oncology

1

Brain metastases occur in approximately 30-40% of lung cancer patients, complicating prognosis and treatment planning.
2

Traditional survival prediction in lung cancer patients with brain metastases relies on clinical scoring systems like the Graded Prognostic Assessment.
3

Recent studies have introduced machine learning and deep learning methods to enhance survival prediction by integrating clinical and radiologic data.
4

Lung-molGPA is noted for providing better survival predictions by incorporating molecular biomarkers compared to traditional scoring systems.
5

Data-driven approaches, including radiomics and machine learning models, show promise in improving survival prediction for lung cancer patients with brain metastases.

Original Source(s)

Frontiers In Oncology

Predictive modeling for survival-related outcomes in lung cancer patients with brain metastases: a mini-review

by Sifat Jahan Shorna, Sreya Majumder, Diya Rahman, Fariha Jahan, Sheak Rashed Haider Noori, Liew Tze Hui, Dip Nandi, Mashiour Rahman
July 14, 2026

Related Content

Jama Network Open

Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A

Nature Medicine

Publisher Correction: Decade-long persistence of CD19 CAR T cells in B cell lymphomas

Dana-Farber

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

by
August 26, 2026
5 min